NO20002998L - Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet - Google Patents
Purinderivater som har fosfodiesterase IV inhibisjonsaktivitetInfo
- Publication number
- NO20002998L NO20002998L NO20002998A NO20002998A NO20002998L NO 20002998 L NO20002998 L NO 20002998L NO 20002998 A NO20002998 A NO 20002998A NO 20002998 A NO20002998 A NO 20002998A NO 20002998 L NO20002998 L NO 20002998L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkylalkyl
- cycloalkenyl
- cycloalkyl
- Prior art date
Links
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Det er beskrevet forbindelser med formelen (I), hvori R3 valgt fra gruppen som består av C,.10-alkyl, C,.10- alkenyl, C3.10-cykloalkyl, C4.10-cykloalkylalkyl eller C3.10-cykloalkenyl, hvori nevnte alkyl, alkenyl, cykloalkyl, cykloalkylalkyl eller cykloalkenyl eventuelt er substituert i en posisjon med hydroksy; eller benzyl, hvori nevnte benzyl eventuelt er substituert i en eller to posisjoner med halogen, alkoksy, cykloalkoksy eller polycykloalkyl, og hvori nevnte alkylenhet på nevnte alkoksy eller cykloalkoksy substituent eventuelt er substituert i en posisjon med hydroksy; R8 er valgt fra gruppen som består av hydrogen, C,.10-alkyl, C,.,0- alkenyl, C3.10-cykloalkyl, C4.10-cykloalkylalkyl eller C3.IO-cykloalkenyl, hvori nevnte alkyl, alkenyl, cykloalkyl, cykloalkylalkyl eller cykloalkenyl eventuelt er substituert i en posisjon med hydroksy; eller benzyl, hvori nevnte benzyl eventuelt er substituert i en eller to posisjoner med halogen, alkoksy, cykloalkoksy eller polycykloalkyl, og hvori nevnte alkylenhet på nevnte alkoksy eller cykloalkoksy eventuelt er substituert i en posisjon med hydroksy; R6' og R6b er uavhengig valgt fra gruppen som består av hydrogen, C,.10-alkyl, C,.IO- alkenyl, C3.]0-cykloalkyl, C4.10-cykloalkylalkyl eller C3.,0-cykloalkenyl, hvori nevnte alkyl, alkenyl, cykloalkyl, cykloalkylalkyl eller cykloalkenyl eventuelt er substituert i en posisjon med hydroksy; og farmasøytisk akseptable salter derav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937197P | 1997-12-12 | 1997-12-12 | |
| PCT/US1998/026293 WO1999031102A1 (en) | 1997-12-12 | 1998-12-11 | Purine derivatives having phosphodiesterase iv inhibition activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002998D0 NO20002998D0 (no) | 2000-06-09 |
| NO20002998L true NO20002998L (no) | 2000-07-19 |
Family
ID=22088545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002998A NO20002998L (no) | 1997-12-12 | 2000-06-09 | Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6037470A (no) |
| EP (3) | EP1044201A4 (no) |
| JP (5) | JP2002508377A (no) |
| KR (3) | KR100349385B1 (no) |
| CN (3) | CN1294590A (no) |
| AT (1) | ATE244243T1 (no) |
| AU (5) | AU1723099A (no) |
| BR (3) | BR9815170A (no) |
| CA (3) | CA2313004A1 (no) |
| DE (3) | DE19882893T1 (no) |
| DK (1) | DK1045849T3 (no) |
| ES (1) | ES2202924T3 (no) |
| GB (2) | GB2346879B (no) |
| HU (3) | HUP0301166A2 (no) |
| NO (1) | NO20002998L (no) |
| PL (1) | PL341108A1 (no) |
| PT (1) | PT1045849E (no) |
| TR (1) | TR200001706T2 (no) |
| WO (5) | WO1999031104A1 (no) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0011182A (pt) * | 1999-04-02 | 2003-06-10 | Euro Celtique Sa | Derivados de purina tendo atividade inibidora de fosfodiesterase iv |
| ATE279113T1 (de) * | 1999-08-12 | 2004-10-15 | Euro Celtique Sa | Hypoxanthin- und thiohypxanthin-verbindungen |
| WO2002098878A1 (en) * | 2001-02-08 | 2002-12-12 | Memory Pharmaceuticals Corporation | Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| CA2494026A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| CA2494028A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| US20040063938A1 (en) * | 2002-09-30 | 2004-04-01 | Pfizer Inc | Process for preparing haloalkyl pyrimidines |
| EA010017B1 (ru) * | 2003-07-10 | 2008-06-30 | Ачиллион Фармасьютикалз, Инк. | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов |
| TW200523262A (en) * | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| EP1697363A2 (en) * | 2003-12-16 | 2006-09-06 | Ranbaxy Laboratories Limited | Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| BRPI0820791A2 (pt) | 2007-12-17 | 2015-06-16 | Lux Innovate Ltd | Composições e métodos para manutenção de sistemas de condução e contenção de fluido |
| MY161598A (en) * | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AP2014007805A0 (en) | 2011-12-28 | 2014-07-31 | Cytokinetics Inc The Regents Of The University Of California | Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20151900A1 (es) | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
| ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2015120133A1 (en) | 2014-02-07 | 2015-08-13 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| WO2017123766A1 (en) * | 2016-01-12 | 2017-07-20 | Sperovie Biosciences, Inc. | Compounds and compositions for the treatment of disease |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844577A (en) | 1958-07-22 | Certificate of correction | ||
| US2956998A (en) | 1960-10-18 | Adenine derivatives and process | ||
| US3215696A (en) * | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US2903455A (en) | 1959-09-08 | Jdnviiiiaisnvhi jo | ||
| US2697709A (en) | 1951-06-14 | 1954-12-21 | Burroughs Wellcome Co | Mercapto heterocycles and method of making |
| US2691654A (en) * | 1952-06-11 | 1954-10-12 | Buroughs Wellcome & Co U S A I | Amino heterocycles and method of making |
| US2966488A (en) * | 1956-07-30 | 1960-12-27 | Shive William | Substituted alkylaminopurines |
| US2957875A (en) | 1957-11-18 | 1960-10-25 | Upjohn Co | Derivatives of purine |
| US3079378A (en) | 1960-02-01 | 1963-02-26 | Upjohn Co | Acylated psicofuranosyladenines |
| BE601946A (no) * | 1960-03-31 | |||
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| FR1548252A (no) | 1961-10-13 | 1968-12-06 | ||
| IL24679A (en) * | 1965-11-24 | 1971-10-20 | Yissum Res Dev Co | Derivatives of 3-methyl purine and methods of preparing the same |
| US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
| US3952001A (en) | 1970-07-01 | 1976-04-20 | The Boots Company Limited | 1-Carbamoyl-1,2,4-triazoles |
| JPS5121529A (ja) | 1974-08-16 | 1976-02-20 | Hitachi Ltd | Pirorinsandometsukizeiseihimakuboshiho |
| USRE31429E (en) | 1977-02-14 | 1983-10-25 | Merck & Co., Inc. | Process for preparation of 9-(dihalobenzyl)adenines |
| GB2041359B (en) * | 1979-01-10 | 1982-12-15 | Ici Ltd | Purine derivatives and their use in the defoliation of cotton plants |
| US4241063A (en) | 1979-08-06 | 1980-12-23 | Bristol-Myers Company | Purine derivatives and their use as bronchodilators |
| US4407802A (en) | 1981-09-28 | 1983-10-04 | Merck & Co., Inc. | 6-Amidino-9-substituted benzyl purines |
| US4361699A (en) | 1981-09-28 | 1982-11-30 | Merck & Co., Inc. | Novel process for the preparation of N6 -alkyl-arprinocid |
| GB2120065B (en) | 1982-04-27 | 1986-01-02 | Michael Frederick Huber | Heating plants |
| US4492592A (en) | 1983-06-06 | 1985-01-08 | Shell Oil Company | Combined desiccation of substantially supercritical CO2 |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US4883801A (en) | 1984-09-07 | 1989-11-28 | The General Hospital Corporation | Xanthine derivative pest control agents |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| WO1987006576A1 (en) | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
| GB8618931D0 (en) | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US4971972A (en) | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| US5270316A (en) | 1989-10-20 | 1993-12-14 | Kyowa Hakko Kogyo Co., Ltd. | Condensed purine derivatives |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| AU3592493A (en) | 1992-01-13 | 1993-08-03 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| ATE150447T1 (de) | 1992-06-15 | 1997-04-15 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
| MX9304571A (es) | 1992-07-28 | 1994-05-31 | Rhone Poulenc Rorer Ltd | Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador. |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| EP0672031B1 (en) | 1992-12-02 | 2003-03-12 | Pfizer Inc. | Catechol diethers as selective pde iv inhibitors |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| TW263495B (no) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| FI951367A7 (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
-
1998
- 1998-12-10 DE DE19882893T patent/DE19882893T1/de not_active Withdrawn
- 1998-12-10 US US09/209,658 patent/US6037470A/en not_active Expired - Lifetime
- 1998-12-10 CA CA002313004A patent/CA2313004A1/en not_active Abandoned
- 1998-12-10 JP JP2000539026A patent/JP2002508377A/ja active Pending
- 1998-12-10 WO PCT/US1998/026339 patent/WO1999031104A1/en not_active Ceased
- 1998-12-10 WO PCT/US1998/026338 patent/WO1999031103A1/en not_active Ceased
- 1998-12-10 AU AU17230/99A patent/AU1723099A/en not_active Abandoned
- 1998-12-10 DE DE19882892T patent/DE19882892T1/de not_active Withdrawn
- 1998-12-10 KR KR1020007005963A patent/KR100349385B1/ko not_active Expired - Fee Related
- 1998-12-10 GB GB0013781A patent/GB2346879B/en not_active Expired - Fee Related
- 1998-12-10 AU AU17228/99A patent/AU1722899A/en not_active Abandoned
- 1998-12-10 CN CN98812098A patent/CN1294590A/zh active Pending
- 1998-12-10 BR BR9815170-3A patent/BR9815170A/pt not_active Application Discontinuation
- 1998-12-10 JP JP2000539028A patent/JP2002508379A/ja active Pending
- 1998-12-10 JP JP2000539027A patent/JP2002508378A/ja active Pending
- 1998-12-10 WO PCT/US1998/026340 patent/WO1999031105A1/en not_active Ceased
- 1998-12-10 US US09/209,922 patent/US6040447A/en not_active Expired - Lifetime
- 1998-12-10 AU AU17229/99A patent/AU1722999A/en not_active Abandoned
- 1998-12-10 HU HU0301166A patent/HUP0301166A2/hu unknown
- 1998-12-10 GB GB0013780A patent/GB2346878B/en not_active Expired - Fee Related
- 1998-12-10 US US09/209,664 patent/US6057445A/en not_active Expired - Fee Related
- 1998-12-10 EP EP98962064A patent/EP1044201A4/en not_active Withdrawn
- 1998-12-11 WO PCT/US1998/026293 patent/WO1999031102A1/en not_active Ceased
- 1998-12-11 JP JP2000539025A patent/JP3504234B2/ja not_active Expired - Fee Related
- 1998-12-11 WO PCT/US1998/026444 patent/WO1999029694A1/en not_active Ceased
- 1998-12-11 CN CN98813362A patent/CN1284077A/zh active Pending
- 1998-12-11 KR KR1020007006407A patent/KR20010033049A/ko not_active Withdrawn
- 1998-12-11 PL PL98341108A patent/PL341108A1/xx unknown
- 1998-12-11 AT AT98963053T patent/ATE244243T1/de not_active IP Right Cessation
- 1998-12-11 US US09/210,556 patent/US6228859B1/en not_active Expired - Fee Related
- 1998-12-11 TR TR2000/01706T patent/TR200001706T2/xx unknown
- 1998-12-11 BR BR9815171-1A patent/BR9815171A/pt not_active Application Discontinuation
- 1998-12-11 JP JP2000524287A patent/JP2001525412A/ja active Pending
- 1998-12-11 EP EP98963053A patent/EP1045849B1/en not_active Expired - Lifetime
- 1998-12-11 CA CA002313150A patent/CA2313150A1/en not_active Abandoned
- 1998-12-11 AU AU18208/99A patent/AU1820899A/en not_active Abandoned
- 1998-12-11 AU AU18159/99A patent/AU747366B2/en not_active Ceased
- 1998-12-11 PT PT98963053T patent/PT1045849E/pt unknown
- 1998-12-11 CA CA002314335A patent/CA2314335A1/en not_active Abandoned
- 1998-12-11 DE DE69816127T patent/DE69816127T2/de not_active Expired - Fee Related
- 1998-12-11 EP EP98963114A patent/EP1045850A4/en not_active Withdrawn
- 1998-12-11 US US09/210,557 patent/US6211367B1/en not_active Expired - Lifetime
- 1998-12-11 HU HU0100417A patent/HUP0100417A3/hu unknown
- 1998-12-11 CN CN98812064A patent/CN1281458A/zh active Pending
- 1998-12-11 BR BR9815169-0A patent/BR9815169A/pt not_active Application Discontinuation
- 1998-12-11 DK DK98963053T patent/DK1045849T3/da active
- 1998-12-11 HU HU0100305A patent/HUP0100305A2/hu unknown
- 1998-12-11 ES ES98963053T patent/ES2202924T3/es not_active Expired - Lifetime
- 1998-12-11 KR KR1020007006328A patent/KR20010032979A/ko not_active Withdrawn
-
2000
- 2000-06-09 NO NO20002998A patent/NO20002998L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002998L (no) | Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet | |
| AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| TR200100241T2 (tr) | Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar | |
| CA2382919A1 (en) | Bicyclic imidazo-3-yl-amine derivatives | |
| DK1401837T3 (da) | Purinderivater som A2B-adenosinreceptorantagonister | |
| CA2116782A1 (en) | 1-substituted 1h-imidazo¬4,5-c|quinolin-4-amines; intermediate and pharmaceutical compositions | |
| CA2387533A1 (en) | Purine derivatives | |
| CA2379786A1 (en) | Purine derivatives | |
| CA2387531A1 (en) | Purine derivatives | |
| CA2194984A1 (en) | 4-indole derivatives as serotonin agonists and antagonists | |
| AU5699399A (en) | Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors | |
| CA2297825A1 (en) | Indole and 2,3-dihydroindole derivatives, their preparation and use | |
| CA2308192A1 (en) | 4'-c-ethynyl pyrimidine nucleoside compounds | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| AU2267495A (en) | Benzamide derivatives as vasopressin antagonists | |
| CA2238875A1 (en) | Tri-aryl ethane derivatives as pde iv inhibitors | |
| HK1046405A1 (zh) | 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物 | |
| WO2000068198A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| MXPA04009162A (es) | Derivados de piperidina u 8-aza-biciclo[3.2.1]oct-3-ilo empleados como moduladores de actividad del receptor de quimiocina (especialmente ccr5). | |
| WO2003008365A3 (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | |
| WO2000059449A3 (en) | Purine derivatives having phosphodiesterase iv inhibition activity | |
| BR0211938A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do dito composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo, e, método para tratar os distúrbios de fertilidade em pacientes em necessidade do mesmo | |
| WO2003082881A3 (en) | Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors | |
| AU2001278708A1 (en) | Adenosine derivatives and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |